Forte Biosciences Files 8-K on Financials

Ticker: FBRX · Form: 8-K · Filed: Apr 4, 2025 · CIK: 1419041

Sentiment: neutral

Topics: financial-reporting, 8-k, results-of-operations

TL;DR

Forte Biosciences dropped its Q1 2025 financial results on an 8-K.

AI Summary

Forte Biosciences, Inc. filed an 8-K on April 4, 2025, reporting on its results of operations and financial condition as of March 31, 2025. The filing includes financial statements and exhibits related to the company's performance.

Why It Matters

This 8-K filing provides investors with an update on Forte Biosciences' financial health and operational results as of the end of the first quarter of 2025.

Risk Assessment

Risk Level: low — This filing is a routine financial disclosure and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Forte Biosciences, Inc.'s Results of Operations and Financial Condition as of March 31, 2025, and to include Financial Statements and Exhibits.

When was this 8-K filed with the SEC?

This 8-K was filed with the SEC on April 4, 2025.

What is the exact name of the company filing this report?

The exact name of the company is Forte Biosciences, Inc.

What is the company's principal executive office address?

The company's principal executive office is located at 3060 Pegasus Park Dr. Building 6, Dallas, Texas 75247.

What is the Commission File Number for Forte Biosciences, Inc.?

The Commission File Number for Forte Biosciences, Inc. is 001-38052.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 4, 2025 regarding Forte Biosciences, Inc. (FBRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing